ScoreWhy is Tango Therapeutics, Inc. ?
1
The company has declared positive results in Jan 70 after 3 consecutive negative quarters
- RAW MATERIAL COST(Y) Fallen by -4.62% (YoY)
- NET SALES(Q) Highest at USD 53.81 MM
- OPERATING PROFIT(Q) Highest at USD 14.63 MM
2
Market Beating performance in long term as well as near term
- Along with generating 787.10% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Tango Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Tango Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Tango Therapeutics, Inc.
813.44%
1.15
113.15%
S&P 500
20.78%
1.08
19.33%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
42.94%
EBIT Growth (5y)
-214.77%
EBIT to Interest (avg)
-114.87
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.29
Sales to Capital Employed (avg)
0.20
Tax Ratio
0.15%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.54
EV to EBIT
-5.34
EV to EBITDA
-5.42
EV to Capital Employed
-19.20
EV to Sales
34.55
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-107.86%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend28What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -4.62% (YoY
NET SALES(Q)
Highest at USD 53.81 MM
OPERATING PROFIT(Q)
Highest at USD 14.63 MM
OPERATING PROFIT MARGIN(Q)
Highest at 27.18 %
PRE-TAX PROFIT(Q)
Highest at USD 15.87 MM
NET PROFIT(Q)
Highest at USD 15.88 MM
EPS(Q)
Highest at USD 0.14
-5What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -145.82 MM
DEBT-EQUITY RATIO
(HY)
Highest at -74.03 %
Here's what is working for Tango Therapeutics, Inc.
Net Sales
At USD 53.81 MM has Grown at 785.89%
over average net sales of the previous four periods of USD 6.07 MMMOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 15.87 MM has Grown at 143.67%
over average net sales of the previous four periods of USD -36.35 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 15.88 MM has Grown at 143.65%
over average net sales of the previous four periods of USD -36.39 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Highest at USD 53.81 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 14.63 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 27.18 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 15.87 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 15.88 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.14
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -4.62% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Tango Therapeutics, Inc.
Operating Cash Flow
Lowest at USD -145.82 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Highest at -74.03 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Non Operating Income
Highest at USD 0.11 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
